N

    Niagen Bioscience, Inc. (NAGE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.13
    -0.16 (-4.86%)

    Market Cap: $247.66M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(22/35)
    Avg Surprise
    +12.47%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $-0.01
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$0.08+900.0%
    60d ago$0.03+400.0%
    30d ago$0.03+400.0%
    7d ago$0.03+400.0%
    Current$-0.01
    Revenue Consensus
    $34M
    Range$32M - $36M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.05
    Range$0.05 - $0.05
    1 analysts
    Revenue Consensus
    $38M
    Range$35M - $40M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.05---
    Sep 26EST
    		-$-0.01---
    Jun 26
    Reported Aug 4
    		$0.01$0.01+0.00%Beat-75.0%
    Mar 26
    Reported May 6
    		$0.02N/A-66.67%Miss-60.0%
    Dec 25
    Reported Mar 4
    		$0.03$0.02+25.45%Beat-69.3%
    Sep 25
    Reported Nov 4
    		$0.05$0.02+150.00%Beat+150.0%
    Jun 25
    Reported Aug 6
    		$0.04$0.01+300.00%Beat+154.8%
    Mar 25
    Reported May 7
    		$0.05$0.02+150.00%Beat+600.0%
    Dec 24
    Reported Mar 4
    		$0.09$0.02+350.00%Beat+5900.0%
    Sep 24
    Reported Oct 31
    		$0.02$0.01+100.00%Beat+300.0%
    Jun 24
    Reported Aug 7
    		$0.02$-0.01+257.00%Beat+152.3%
    Mar 24
    Reported May 8
    		$-0.01$-0.01+0.00%Beat+66.7%
    Dec 23
    Reported Mar 6
    		$0.00N/A+106.67%Beat+107.5%
    Sep 23
    Reported Nov 8
    		$-0.01N/A+66.67%Beat+0.0%
    Jun 23
    Reported Aug 9
    		$-0.03$-0.04+25.00%Beat+66.7%
    Mar 23
    Reported May 10
    		$-0.03$-0.05+40.00%Beat+72.7%
    Dec 22
    Reported Mar 8
    		$-0.02$-0.02+0.00%Beat+75.0%
    Sep 22
    Reported Nov 2
    		$-0.01N/A+83.33%Beat+92.3%
    Jun 22
    Reported Aug 10
    		$-0.09$-0.09+0.00%Beat-12.5%
    Mar 22
    Reported May 12
    		$-0.11$-0.09-22.22%Miss+8.3%
    Dec 21
    Reported Mar 9
    		$-0.08$-0.08+0.00%Beat+20.0%
    Sep 21
    Reported Nov 3
    		$-0.13$-0.09-44.44%Miss-85.7%
    Jun 21
    Reported Aug 3
    		$-0.08$-0.08+0.00%Beat-33.3%
    Mar 21
    Reported May 6
    		$-0.12$-0.08-50.00%Miss-20.0%
    Dec 20
    Reported Mar 10
    		$-0.10$-0.10+0.00%Beat+32.6%
    Sep 20
    Reported Nov 4
    		$-0.07$-0.09+22.22%Beat+41.7%
    Jun 20
    Reported Aug 6
    		$-0.06$-0.10+40.00%Beat+57.1%
    Mar 20
    Reported May 11
    		$-0.10$-0.11+9.09%Beat+33.3%
    Dec 19
    Reported Mar 11
    		$-0.15N/AN/ABeat+0.3%
    Sep 19
    Reported Nov 12
    		$-0.12$-0.11-9.09%Miss+25.0%
    Jun 19
    Reported Aug 7
    		$-0.14$-0.13-7.69%Miss+6.7%
    Mar 19
    Reported May 9
    		$-0.15$-0.12-25.00%Miss+0.0%
    Dec 18
    Reported Mar 31
    		$-0.15N/AN/ABeat+13.6%
    Sep 18
    Reported Nov 7
    		$-0.16$-0.12-33.33%Miss-128.6%
    Jun 18
    Reported Aug 9
    		$-0.15$-0.13-15.38%Miss-200.0%
    Mar 18
    Reported May 10
    		$-0.15$-0.06-150.00%Miss-200.0%
    Dec 17
    Reported Mar 31
    		$-0.17N/AN/ABeat-204.6%
    Sep 17
    Reported Nov 9
    		$-0.07$-0.05-40.00%Miss-177.8%
    Jun 17
    Reported Aug 10
    		$-0.05$0.04-225.00%Miss-
    Mar 17
    Reported May 11
    		$-0.05$0.01-600.00%Miss-
    Dec 16
    Reported Mar 31
    		$-0.06N/AN/ABeat-
    Sep 16
    Reported Nov 11
    		$-0.03N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio29.09EV/EBITDA18.45x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin12.40%Operating Margin2.35%
    ROE21.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.50xQuick Ratio5.13x
    Trading Statistics
    Beta2.10Avg Volume637.70K
    52-Week High$10.5252-Week Low$2.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.20
    SMA 20$3.14
    SMA 50$3.28
    SMA 200$4.74
    EMA 10$3.20
    EMA 20$3.20
    EMA 50$3.33
    EMA 200$4.69

    MACD

    Line: -0.02Signal: -0.04Hist: 0.02

    ADX

    ADX: 13.4+DI: 20.6-DI: 22.4

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down28.0
    PSAR$3.39

    Bollinger Bands

    Upper Band$3.39
    Lower Band$2.90
    %B Position1569%(Upper)
    Band Width0.47

    RSI (14-Day)

    Neutral
    45.7

    Momentum Oscillators

    Stoch %K67.1
    Stoch %D78.9
    Williams %R-53.9
    ROC (10d)3.0%
    Momentum0.09
    CCI (20d)20.8
    MFI (14d)57.6

    Volatility Measures

    ATR (14d)$0.14(4.3%)
    StdDev (20d)0.12
    Hist Vol62.5%(High)

    Volume Flow

    VWAP$3.17
    OBV22.7M
    AD Line-19.8M
    CMF (20d)0.108

    Volume Metrics

    Avg Vol (20d)606.4K
    Vol Ratio0.8x
    VWMA (20d)$3.13

    Pivot Points

    R3$3.43
    R2$3.37
    R1$3.33
    Pivot Point$3.26
    S1$3.23
    S2$3.16
    S3$3.12

    Advanced Oscillators

    TSI-3.56
    Ultimate Osc50.7
    KST-36.20

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$29.79M$31.47M$33.84M$33.99M$31.12M$30.48M$29.13M$25.58M$22.74M$22.15M$21.20M$19.50M
    Cost of Revenue$10.47M$11.50M$12.13M$12.06M$10.89M$11.15M$10.93M$9.34M$9.05M$8.70M$8.26M$7.53M
    Gross Profit$19.31M$19.98M$21.70M$21.93M$20.23M$19.33M$18.20M$16.24M$13.69M$13.46M$12.94M$11.97M
    Operating Expenses$18.61M$18.40M$17.62M$17.69M$17.04M$14.56M$11.09M$14.64M$13.95M$14.19M$13.11M$13.12M
    R&D$1.51M$1.48M$1.71M$1.79M$1.57M$1.26M$1.31M$1.29M$1.32M$2.10M$1.16M$1.24M
    SG&A$6.97M$7.24M$7.48M$7.13M$7.27M$5.18M$1.05M$6.30M$5.66M$5.35M$5.43M$5.84M
    Operating Income$700,000$1.58M$4.09M$4.24M$3.19M$4.77M$7.11M$1.60M$-256,000$-731,000$-168,000$-1,147,000
    Interest Income$372,000$375,000$552,000$564,000$552,000$459,000$373,000$276,000$241,000$239,000$0$188,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$1.07M$6.74M$4.42M$4.80M$3.74M$5.23M$7.48M$1.88M$-15,000$-492,000$114,000$-959,000
    Income Tax Expense$106,000$417,000$292,000$222,000$128,000$168,000$305,000$0$0$0$0$0
    Net Income$963,000$6.32M$4.13M$4.58M$3.61M$5.06M$7.18M$1.88M$-15,000$-492,000$114,000$-959,000
    EBITDA$988,000$6.65M$4.29M$4.43M$3.38M$4.97M$7.30M$1.80M$-49,000$-515,000$-472,000$-699,000
    EBIT$697,000$6.36M$4.09M$4.24M$3.19M$4.77M$7.11M$1.60M$-256,000$-731,000$-168,000$-1,147,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NAGE

    News

    Niagen Bioscience stock gains GNC, Sam’s Club distribution, Canaccord reiterates buy

    Niagen Bioscience (NASDAQ:NAGE) has announced expanded retail distribution for its Tru Niagen NAD+ supplement, now available at GNC and Sam’s Club stores. Canaccord Genuity reiterated a Buy rating and a $10.00 price target, citing the expanded distribution and the company's innovation pipeline. The company is also making strides in rare genetic disease treatments with its subsidiary NAD Pharmaceuticals Corp.

    Investing.com Canada•8/24/26•
    Bullish

    Niagen Bioscience lists Tru Niagen supplement on Walmart.com

    Niagen Bioscience announced that its Tru Niagen NAD+ supplement is now available on Walmart.com, starting with 300 mg in 30-count and 90-count bottles, with plans for further expansion. CEO Rob Fried stated this move increases accessibility for their "science-backed NAD+ solution." The company highlights Tru Niagen's clinical backing and market position as the leading NAD+ boosting oral supplement in the U.S.

    Investing.com•8/24/26•
    Bullish

    Niagen Bioscience Leads The Way With 2 Promising Penny Stocks

    This article highlights several penny stocks with strong financial foundations and growth potential, despite the U.S. market's recent dip. It focuses on Niagen Bioscience (NAGE), Nutriband (NTRB), and Definitive Healthcare (DH), detailing their market caps, operational revenues, recent financial performance, and strategic positioning within their respective industries. The analysis aims to identify promising opportunities for investors interested in smaller, high-growth companies.

    Sahm•8/22/26•
    Somewhat-Bullish

    Niagen Bioscience Leads The Way With 2 Promising Penny Stocks

    This article highlights two penny stocks, Niagen Bioscience (NAGE) and Nutriband (NTRB), that show promise despite the inherent volatility of smaller companies. Niagen Bioscience, with a market cap of US$251.36 million, is expanding its healthy aging products and maintains a debt-free balance sheet. Nutriband, valued at US$43.15 million, is developing transdermal pharmaceutical products and has strengthened its financial position with a new credit line.

    Simply Wall Street•8/21/26•
    Somewhat-Bullish

    Supplement Retail Expansions

    Niagen Bioscience has expanded the retail availability of its Tru Niagen product line, including Tru Niagen Beauty, into GNC and Sam's Club stores across 44 states. This move signifies a broader trend of science-backed healthy aging supplements transitioning from niche wellness shops to mainstream retail, making advanced cellular health products more accessible to everyday consumers. The expansion highlights growing consumer interest in NAD+ support for cellular energy, mitochondrial function, and DNA repair, as well as the increasing market for beauty-from-within ingestible supplements.

    Trend Hunter•8/20/26•
    Neutral

    Frequently Asked Questions About NAGE

    Does NAGE pay dividends?
    Niagen Bioscience, Inc. (NAGE) does not currently pay a regular dividend.
    What is NAGE's P/E ratio?
    Niagen Bioscience, Inc. has a price-to-earnings (P/E) ratio of 29.09.
    What is NAGE's market cap?
    Niagen Bioscience, Inc. (NAGE) has a market capitalization of $247.66M with a current stock price of $3.13.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In